(0)
(1)
(0)
keyboard_arrow_left keyboard_arrow_right

Key information keyboard_arrow_right

Key info that gives quick info on the case
Description Value
Database last updated
Description / title Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi
Status
Legal status
Detailed status 		Not in force Ceased Patent protection period expired (check also details in the case)
Patent number 332893
Application number 20010699
Filed
Divided to 20111217;
Priority 1998.08.11, US 96180
Case type PCT
Registered internationally
International application number PCT/US1999/18120
Entry into National Phase
Effective date
Expiry date
Publicly available
Granted
Applicant Biogen Idec Inc (US)
Owner Biogen Inc. (US)
Inventor Antonio Grillo-López (US)
Agent OSLO PATENTKONTOR AS (NO)
Patent family Look up in Espacenet

Abstract and drawing keyboard_arrow_right


Nye kombinerte terapeutiske regimer for behandling av B- celle-lymfomer er beskrevet og som omfatter spesielt administrasjon av anti-CD20-antistoff til pasienter som har lav-, mellomliggende- eller høygrads non-Hodgkins lymfom.

View the abstract and front page figure in Espacenet

Classes keyboard_arrow_right

IPC class

A61K 39/395 A61P 35/00  

CPC class

A61K 39/39558  

Applicant(s) keyboard_arrow_right

Biogen Idec Inc
5200 Research Place CA92122 SAN DIEGO US

Owner keyboard_arrow_right

Biogen Inc.
225 Binney Street MA02142 CAMBRIDGE US
NIPO's case no. 2016/01675
Your reference: 110774SPC TG/AT   Filed  
Current status Settled

Sender

OSLO PATENTKONTOR AS
Hoffsveien 1A 0275 OSLO NO ( OSLO Municipality, OSLO county )

Org. number: 910476068

Status history for 2016/01675

List over status changes in case history
Legal status Decision date, detailed status
Settled Request completed
Pending Received at office

Correspondence for 2016/01675

add_circle_outline   save_alt  
List of case history and correspondence
Date Correspondence type Journal description
Outgoing GH Forespørsel
03-01 AltUt sending GH Forespørsel
Outgoing GH Forespørsel
02-01 AltUt sending GH Forespørsel
Incoming E-post
01-01 General request correspondence E-post
01-02 Request for Assignement Endringsskjema
Information about documents which are not available

Inventor keyboard_arrow_right

Antonio Grillo-López
Alexandria, VA US

Agent keyboard_arrow_right

Agent in Norway:
OSLO PATENTKONTOR AS
Hoffsveien 1A 0275 OSLO NO ( OSLO Municipality, OSLO county )

Org. number: 910476068
Your reference: 144046 TG/eah
  • Organization name:
  • Organization form:
  • Industry:
  • Organization address:
     

Source: The Brønnøysund Register Centre

Priority keyboard_arrow_right

1998.08.11, US 96180

Citations (cited documents) keyboard_arrow_right

US 5736137 A (A)

MALONEY, D.G. et al,IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed Non-Hodgkin's lymphoma. Jour. of Clinic. Oncol., 1997.10, Vol. 15, No. 10, s. 3266-74 ()

MCLAUGHLIN, P. et al, Rituximab chimeric anti-CD20 monoklonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. 1998.08, Vol. 16, No. 8, s. 2825-33 ()

VAN DER KOLK, L.E. et al., Chimeric anti-CD20 monoklonal antibody (Rituximab) plus G-CSF in relapsed B-cell lymphoma: A phase I/II clinical trial, 1998.07.01, Brit. Jour. of haematol., Vol. 102, No. 1, sammendrag ()

US 5736137 A (A)

MALONEY, D.G. et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed Non-Hodgkin's lymphoma. Jour. of Clinic. Oncol., 1997.10, Vol. 15, No. 10, s. 3266-74, ()

MCLAUGHLIN, P. et al. Rituximab chimeric anti-CD20 monoklonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. 1998.08, Vol. 16, No. 8, s. 2825-33, ()

VAN DER KOLK, L.E. et al.Chimeric anti-CD20 monoklonal antibody (Rituximab) plus G-CSF in relapsed B-cell lymphoma: A phase I/II clinical trial, 1998.07.01, Brit. Jour. of haematol., Vol. 102, No. 1. ()

ARRANZ REYES, ET AL., Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. Jour. Clin. Oncol. April 1998; Vol. 16(4), s. 1538-46. ()

Hochster, H. S. ET AL., Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood (ASH Annual Meeting Abstracts), 2005, 106: Abstract 349. ()

Administrative review keyboard_arrow_right

NIPO's case no. 2017/00085
Filed  
Current status Performed

Claimant

OSLO PATENTKONTOR AS
Hoffsveien 1A 0275 OSLO NO ( OSLO Municipality, OSLO county )

Org. number: 910476068
  • Organization name:
  • Organization form:
  • Industry:
  • Organization address:
     

Source: The Brønnøysund Register Centre

Claimant's agent

OSLO PATENTKONTOR AS
Hoffsveien 1A 0275 OSLO NO ( OSLO Municipality, OSLO county )

Org. number: 910476068
  • Organization name:
  • Organization form:
  • Industry:
  • Organization address:
     

Source: The Brønnøysund Register Centre

Status history for 2017/00085

List over status changes in case history
Legal status Decision date, detailed status
Performed The right has been changed as a result of administrative review or patent limitation
Pending Letter with due date issued
Pending Letter with due date issued
Pending Received

Correspondence for 2017/00085

add_circle_outline   save_alt  
List of case history and correspondence
Date Correspondence type Journal description
Outgoing OP10: Oversendelsesbrev med avgjørelse uten klagefrist
05-01 AltUt sending OP10: Oversendelsesbrev med avgjørelse uten klagefrist
05-02 Attachment IAAB10 - Avgjørelse - administrativ begrensning_819558
Incoming, AR186070508 Korrespondanse (Hovedbrev inn)
04-01 General letter or reply on time limit Korrespondanse (Hovedbrev inn)
Outgoing Mangelbrev
03-01 AltUt sending Mangelbrev
Incoming, AR185167762 Korrespondanse (Hovedbrev inn)
02-01 General letter or reply on time limit Korrespondanse (Hovedbrev inn)
02-02 Other document Stevning til Oslo Tingrett
02-03 Other document Tilsvar til Oslo tingrett 28.02.17
02-04 Main letter Hovedbrev
Incoming, AR184889052 Nytt overprøvningskrav (OP)
01-01 OP Application form Nytt overprøvningskrav (OP)
01-02 Main letter Hovedbrev
01-03 Documentation of arguments Dokumentasjon av krav
Information about documents which are not available

Case history keyboard_arrow_right

Status history

List over status changes in case history
Legal status Decision date, detailed status
Ceased Patent protection period expired
Granted Granted (B3) with changes after administrative overruling or administrative reevaluation
Granted Message about invalidation case or transfer of patent case for court has been received.
Granted Granted (B1)
Pending Accepted for grant
Pending Second and later letter exists
Pending Second and later letter exists
Pending Second and later letter exists
Pending Second and later letter exists
Pending Case handling is resumed
Shelved Not answered in due time (PL § 15)
Pending Second and later letter exists
Pending First letter of examination exists
Pending New application created

Correspondence

add_circle_outline   save_alt  
List of case history and correspondence
Date Correspondence type Journal description
Outgoing PT Utløpt 20 år (3315)
23-01 AltUt sending PT Utløpt 20 år (3315)
Incoming, AR184889052 Krav
22-01 Patent claims Krav
Outgoing Bekreftelse mottatt melding om søksmål
21-01 Outgoing Letter Bekreftelse mottatt melding om søksmål
Incoming Melding om søksmål
20-01 Main letter Melding om søksmål
Outgoing PT Registreringsbrev Nasjonal Patent
19-01 Outgoing Letter PT Registreringsbrev Nasjonal Patent
Outgoing PT Meddelelse om patent
17-01 AltUt sending PT Meddelelse om patent
Incoming Korrespondanse (hoved dok)
16-01 General letter or reply on time limit Korrespondanse (hoved dok)
16-02 Main letter Hovedbrev
16-03 Patent Description Beskrivelse
Outgoing Realitet patent
15-01 AltUt sending Realitet patent
Incoming Korrespondanse (hoved dok)
14-01 General letter or reply on time limit Korrespondanse (hoved dok)
14-02 Main letter Hovedbrev
14-03 Patent claims Krav
Outgoing Realitet patent
13-01 AltUt sending Realitet patent
Incoming Korrespondanse (hoved dok)
12-01 General letter or reply on time limit Korrespondanse (hoved dok)
12-02 Patent claims Krav
12-03 Main letter Hovedbrev
Outgoing Realitet patent
11-01 AltUt sending Realitet patent
Incoming Korrespondanse (hoved dok)
10-01 General letter or reply on time limit Korrespondanse (hoved dok)
10-02 Main letter Hovedbrev
10-03 Patent claims Krav
Outgoing Realitet patent
09-01 AltUt sending Realitet patent
Incoming Korrespondanse (hoved dok)
08-01 General letter or reply on time limit Korrespondanse (hoved dok)
08-02 Other document Annet dokument
08-03 Main letter Hovedbrev
08-04 Patent claims Krav
Outgoing Henlagt manglende svar
07-01 AltUt sending Henlagt manglende svar
Outgoing Henlagt manglende svar
06-01 AltUt sending Henlagt manglende svar
Outgoing Realitet patent
05-01 AltUt sending Realitet patent
05-02 Attachment PT report 03:49:08
Incoming Korrespondanse (hoved dok)
04-01 General letter or reply on time limit Korrespondanse (hoved dok)
04-02 Patent claims PT - 7 Krav
04-03 Main letter PT - 7 Hovedbrev
Incoming Korrespondanse (hoved dok)
03-01 General letter or reply on time limit Korrespondanse (hoved dok)
03-02 Main letter Hovedbrev
Incoming Korrespondanse (hoved dok)
02-01 General letter or reply on time limit Korrespondanse (hoved dok)
02-02 Main letter Hovedbrev
Outgoing PT Realitet_patent (2009.04.01)
01-01 Outgoing Letter PT Realitet_patent (2009.04.01)
Information about documents which are not available

Payment keyboard_arrow_right

Payment due:

Payment history:

List of payments
Description / Invoice number Payment date Amount Payer Status
Annual fee 20th year 2018.07.26 6500 MASTER DATA INC Paid and approved
Annual fee 19th year 2017.07.26 6200 MASTER DATA INC Paid and approved
Annual fee 18th year 2016.07.25 5800 MASTER DATA INC Paid and approved
Annual fee 17th year 2015.07.27 5500 Master Data Center Inc Paid and approved
Annual fee 16th year 2014.07.25 5200 Master Data Center Inc Paid and approved
Annual fee 15th year 2013.07.26 4400 Master Data Center Inc Paid and approved
31213747 2012.11.09 7100 Oslo Patentkontor AS Paid
Annual fee 14th year 2012.08.09 4100 Computer Patent Annuities Ltd Paid and approved
Annual fee 13th year 2011.07.20 3800 Computer Packages Inc Paid and approved
31013977 2010.12.07 900 Oslo Patentkontor AS Paid
Annual fee 12th year 2010.07.21 2850 Computer Packages Inc Paid and approved
Annual fee 11th year 2009.07.21 2850 Computer Packages Inc
Annual fee 10th year 2008.07.21 2850 Computer Packages Inc
Annual fee 9th year 2007.07.19 1900 Computer Packages Inc
Annual fee 8th year 2006.07.19 1900 Computer Packages Inc
Annual fee 7th year 2005.07.21 1900 Computer Packages Inc
Annual fee 6th year 2004.08.11 1000 Computer Patent Annuities Ltd
0
0
0
This economic overview may lack information, particularly for older cases, for reimbursements, international trademarks and international designs.

Publication(s) keyboard_arrow_right

Links to publications and the Norwegian Patent Gazette (searchable text documents)

Last published version of the patent
Link to patent application / extract (when open for public inspection)
Link to the Norwegian Patents Gazette - when granted
Links to publications (only image files)
B3
B1
A

What does A1, B, B1, C stand for?

keyboard_arrow_left keyboard_arrow_right
Chapters without data are removed. Document created: 18.04.2021 02:02:39